Hims GLP-1 Program Review: Cost, Medications, and Patient Experience

Last Updated: March 2026

In the landmark STEP 1 clinical trial, participants treated with semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% of their initial body weight, compared to 2.4% for the placebo group over 68 weeks (New England Journal of Medicine, 2021) [1]. This clinical efficacy underpins the surge in demand for GLP-1 receptor agonists, making them a cornerstone of modern medical weight management. Telehealth platforms, including Hims & Hers, have rapidly entered this space, aiming to expand access to these transformative medications. This review critically examines the Hims GLP-1 program, focusing on its cost structure, the specific medications it offers, the quality of its prescriber network, and the overall patient experience, providing a data-driven perspective for prospective users.

Understanding Hims & Hers and Its Entry into Weight Management

Hims & Hers Health, Inc. began as a direct-to-consumer telehealth platform, primarily known for addressing conditions often associated with stigma, such as hair loss, erectile dysfunction, and mental health. Their model prioritizes convenience and accessibility, allowing patients to consult with licensed providers remotely and receive prescriptions delivered to their homes. The company’s expansion into weight management with GLP-1s represents a significant strategic move, capitalizing on the high demand and the increasing acceptance of telehealth for chronic condition management.

The Hims GLP-1 program is designed to simplify the process of obtaining weight loss medication. It typically begins with an online assessment, followed by a virtual consultation with a licensed medical professional. Based on a patient’s medical history, weight profile, and other factors, a provider may prescribe either compounded semaglutide injections or oral semaglutide. This approach positions Hims as a more affordable, accessible alternative to traditional in-person clinic visits and high-cost brand-name medications.

Medications Offered: Compounded vs. FDA-Approved

Hims primarily offers two forms of GLP-1 medications for weight loss: compounded semaglutide injections and oral semaglutide. Understanding the distinctions between these offerings is crucial for patient decision-making.

Compounded Semaglutide Injections

Compounded drugs are custom-prepared medications made by a licensed pharmacist or physician for an individual patient. In the context of GLP-1s, compounded semaglutide is created using the active pharmaceutical ingredient (API) semaglutide, but it is not an FDA-approved drug product itself. The FDA has a clear stance on compounded GLP-1s. As explicitly stated by the agency, “Compounded drugs are not FDA-approved. This means they do not undergo the same rigorous FDA review for safety, effectiveness, and quality as FDA-approved drugs” [2].

This lack of FDA approval carries significant implications:

• Safety and Efficacy: The purity, potency, and sterility of compounded semaglutide can vary significantly because they are not subject to the same manufacturing standards, testing, and oversight as FDA-approved medications like Wegovy or Ozempic. This means the actual dosage or ingredients might differ from what is prescribed, posing potential health risks.
• Ingredient Variations: Compounded versions may also include different salts of semaglutide (e.g., semaglutide sodium) or other additives not present in the FDA-approved formulations. The safety and efficacy of these variations are not clinically established.
• Supply Chain Transparency: The source and quality of the raw active pharmaceutical ingredient (API) used in compounding can be opaque, raising concerns about potential contamination or substandard materials.

Patients considering compounded semaglutide must weigh the cost savings against these inherent uncertainties regarding quality control and regulatory oversight. While compounding pharmacies are regulated by state boards of pharmacy, this oversight differs substantially from the FDA’s comprehensive drug approval process.

Oral Semaglutide (Rybelsus Equivalent)

Hims also offers oral semaglutide, which is conceptually equivalent to Rybelsus, the FDA-approved oral form of semaglutide for type 2 diabetes management and blood sugar control. While Rybelsus is not FDA-approved specifically for chronic weight management, studies have shown that semaglutide, regardless of its delivery method, aids in weight loss. Oral semaglutide offers a needle-free alternative, which can be a significant advantage for patients with needle aversion.

However, oral semaglutide has specific administration requirements, such as taking it with a small amount of water (no more than 4 ounces) at least 30 minutes before the first food, drink, or other oral medications of the day. Adherence to these guidelines is critical for optimal absorption and efficacy. While this option typically uses an FDA-approved API, its use by Hims for weight loss may be an off-label prescription if it’s the brand-name Rybelsus, or it might be a compounded oral form. The distinction is important, as compounded oral semaglutide carries the same risks as compounded injectable forms regarding lack of FDA oversight. Given the recent crackdown on unapproved compounded drugs, Hims’ offerings are likely to align with stricter interpretations of compounding rules or shift towards legitimate off-label prescriptions where appropriate.

Cost Analysis: A Key Differentiator

The cost of GLP-1 medications is a primary barrier for many patients, with brand-name injectables like Wegovy (semaglutide) and Zepbound (tirzepatide) often exceeding $1,000 to $1,600 per month without insurance coverage. Hims, along with other telehealth providers specializing in compounded medications, aims to dramatically reduce this financial burden.

Based on recent market trends and competitive offerings from similar telehealth platforms, Hims’ pricing for its GLP-1 program is designed to be significantly more accessible. While exact Hims pricing can fluctuate and is best confirmed directly on their platform, industry context suggests competitive rates. For example, some online programs offer compounded semaglutide starting from $145 per month, and oral semaglutide options can begin even lower, potentially $49 for an initial month, then $99/month for longer plans, as seen with competitors [4]. Hims is positioned within this competitive landscape, offering programs typically in the range of $149 to $299 per month, depending on the specific medication, dosage, and promotional offers. This monthly fee typically covers:

• Virtual consultations with a licensed provider.
• The prescribed medication (compounded semaglutide or oral semaglutide).
• Ongoing support or messaging capabilities with the care team.

This contrasts sharply with the out-of-pocket costs for FDA-approved brand-name medications. For patients without comprehensive insurance coverage for weight loss medications, Hims presents a compelling financial alternative. However, it is essential to consider what is included in that price beyond just the medication itself, such as lab testing, personalized coaching, and the level of clinical oversight.

Insurance and Payment

As a general rule, Hims’ GLP-1 programs, particularly those involving compounded medications, are typically not covered by health insurance. This is largely because compounded drugs lack an FDA National Drug Code (NDC) and therefore do not register in standard pharmacy benefit management systems. Patients should expect to pay for the Hims program entirely out-of-pocket. For oral semaglutide, if Hims is prescribing the brand-name Rybelsus, there is a possibility of insurance coverage, especially if the patient also has type 2 diabetes. However, for weight loss alone, coverage remains highly variable and often denied.

Prescriber Quality and Clinical Oversight

The quality of medical supervision is paramount in GLP-1 therapy due to potential side effects and the need for dosage titration. Hims operates on a telehealth model, which relies heavily on the qualifications of its remote providers and the robustness of its clinical protocols.

Provider Licensing and Expertise

Hims states that its network consists of licensed medical providers, including physicians, physician assistants, and nurse practitioners. These professionals are licensed in the states where they practice and are expected to adhere to standard medical practice guidelines. The initial assessment process typically involves a detailed questionnaire about a patient’s medical history, current medications, existing conditions, and weight loss goals. This information is reviewed by a provider to determine eligibility and suitability for GLP-1 therapy.

Clinical Protocols

A key aspect of responsible GLP-1 prescribing, especially in a telehealth context, is the implementation of robust clinical protocols. These should include:

• Eligibility Screening: Ensuring patients meet established criteria (e.g., BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity), and ruling out contraindications (e.g., personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2).
• Lab Testing: Regular lab work, including blood tests to monitor kidney and liver function, and potentially A1C, is crucial before and during treatment. Hims’ program details should clarify how lab testing is integrated, whether it’s ordered directly or if patients are expected to obtain it independently.
• Dosage Titration: GLP-1 medications require a gradual increase in dosage over several weeks or months to minimize gastrointestinal side effects. Providers should carefully manage this titration schedule, checking in with patients regularly.
• Side Effect Management: Nausea, vomiting, diarrhea, and constipation are common side effects. Providers must be accessible for guidance on managing these issues.

While Hims’ platform facilitates access, the onus is often on the patient to be transparent and proactive in sharing health updates. The convenience of telehealth must be balanced with the clinical rigor required for safe and effective weight loss medication management.

Patient Experience and Support

The patient experience with Hims is largely defined by its digital-first approach.

Initial Assessment and Consultation

The process typically begins with an online health questionnaire. This comprehensive assessment gathers information about medical history, current health status, lifestyle, and weight loss goals. Following the assessment, patients are scheduled for a virtual consultation with a licensed Hims provider. This consultation is crucial for the provider to evaluate the patient’s suitability for GLP-1 therapy, discuss potential risks and benefits, and answer questions. The convenience of conducting this from home is a significant draw.

Ongoing Communication and Support

Once prescribed, patients generally have access to their Hims provider or care team through secure messaging on the platform. This allows for questions about medication, side effects, or dosage adjustments. The level of proactive outreach from Hims’ providers can vary; patients are often expected to initiate contact when needed. Some programs may include additional resources like educational content or basic dietary guidance, though Hims’ core offering focuses primarily on medication access.

Medication Delivery

Medications are typically shipped directly to the patient’s home, usually in discreet packaging. For compounded injectables, clear instructions on preparation, administration, and storage are provided. The convenience of home delivery eliminates pharmacy visits.

Challenges and Considerations

While convenient, the telehealth model can have limitations:

• Lack of Physical Exam: Remote consultations do not allow for physical examinations, which can be important for a comprehensive health assessment, especially for long-term conditions.
• Patient Responsibility: Patients must be diligent in monitoring their health,